Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.

ABSTRACT:

Background

Recently released results from a randomized controlled trial have shown that 13-valent pneumococcal conjugate vaccine (PCV13) is efficacious against vaccine-type nonbacteremic pneumonia in adults.

Objective

We examined the incremental cost-effectiveness of adding PCV13 to the Advisory Committee on Immunization Practices (ACIP) adult immunization schedule.

Methods

We used a probabilistic model following cohorts of 50-, 60-, or 65-year-olds. We used separate vaccination coverage and disease incidence data for healthy and high-risk adults. Incremental cost-effectiveness ratios were determined for each potential vaccination strategy.

Results

In the base case scenario, our model indicated that adding PCV13 at age 65 or replacing 23-valent pneumococcal pol

SUBMITTER: Stoecker C 

PROVIDER: S-EPMC4945555 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature